News Releases

June 29, 2020 6/29/2020 Takeda Announces Pricing of its Unsecured U.S. Dollar-Denominated Senior Notes and Unsecured Euro-Denominated Senior Notes

June 29, 2020 6/29/2020 Takeda Announces Anticipated Financial Impact from Novartis’ Withdrawal of the Marketing Authorisation Application for Xiidra®

June 25, 2020 6/25/2020 Takeda Announces Proposed Issuance of Unsecured U.S. Dollar-Denominated Senior Notes and Unsecured Euro-Denominated Senior Notes

June 24, 2020 6/24/2020 Takeda Announces the Publication of its Annual Report on Form 20-F for FY2019

June 24, 2020 6/24/2020 Notice Concerning Filing of Shelf Registration Statement in Japan for the Issuance of New Shares

June 24, 2020 6/24/2020 Launch of a New Employee Stock Purchase Plan and Long-Term Incentive Plan for Company Group Employees Overseas

June 24, 2020 6/24/2020 Takeda Announces New Assignments of Directors

June 23, 2020 6/23/2020 Takeda Receives U.S. FDA Approval to Manufacture ENTYVIO® (vedolizumab) Drug Substance at Manufacturing Facility in Brooklyn Park, Minnesota

June 22, 2020 6/22/2020 Update of the Financial Impact of the European Commission’s Decision to Release Takeda from Commitment to Divest Shire’s Pipeline Compound SHP647

June 2020